Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiológicos Latinoamérica) Collaborative Group
- PMID: 9867443
- DOI: 10.1161/01.cir.98.21.2227
Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiológicos Latinoamérica) Collaborative Group
Abstract
Background: Several trials have been performed in the past using glucose, insulin, and potassium infusion (GIK) for the treatment of acute myocardial infarction (AMI). Because of continuing uncertainty about the potential role of this therapeutic intervention, we conducted a randomized trial to evaluate the impact of a GIK solution during the first hours of AMI.
Methods and results: Four hundred seven patients with suspected AMI admitted within 24 hours of symptoms onset were enrolled. In a ratio of 2:1, 268 patients were allocated to receive GIK (high- or low-dose) and 139 to receive control. Phlebitis and serum changes in the plasma concentration of glucose or potassium were observed more often with GIK. A trend toward a nonsignificant reduction in major and minor in-hospital events was observed in patients allocated to GIK. In 252 patients (61.9%) treated with reperfusion strategies, a statistically significant reduction in mortality (relative risk [RR] 0.34; 95% CI: 0.15 to 0.78; 2P=0.008) and a consistent trend toward fewer in-hospital events in the GIK group were observed.
Conclusions: Our results confirm that a metabolic modulation strategy in the first hours of an AMI is feasible, applicable worldwide, and has mild side effects. The statistically significant mortality reduction in patients who underwent a reperfusion strategy might have important implications for the management of AMI patients. It is now essential to perform a large-scale trial to reliably determine the magnitude of benefit.
Similar articles
-
Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction.JAMA. 2007 Nov 28;298(20):2399-405. doi: 10.1001/jama.298.20.2399. JAMA. 2007. PMID: 18042917 Clinical Trial.
-
High-dose glucose-insulin-potassium treatment reduces myocardial apoptosis in patients with acute myocardial infarction.Eur J Clin Invest. 2005 Mar;35(3):164-70. doi: 10.1111/j.1365-2362.2005.01468.x. Eur J Clin Invest. 2005. PMID: 15733070 Clinical Trial.
-
Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial.JAMA. 2005 Jan 26;293(4):437-46. doi: 10.1001/jama.293.4.437. JAMA. 2005. PMID: 15671428 Clinical Trial.
-
Glucose-insulin-potassium solution for acute myocardial infarction.Ann Pharmacother. 2002 Jun;36(6):1080-4. doi: 10.1345/aph.1A300. Ann Pharmacother. 2002. PMID: 12022912 Review.
-
Glucose-insulin-potassium (GIK) for acute myocardial infarction: a negative study with a positive value.Cardiovasc Drugs Ther. 1999 May;13(3):185-9. doi: 10.1023/a:1007757407246. Cardiovasc Drugs Ther. 1999. PMID: 10439880 Review.
Cited by
-
Effects of high-dose glucose-insulin-potassium on acute coronary syndrome patients receiving reperfusion therapy: a meta-analysis.World J Emerg Med. 2024;15(3):181-189. doi: 10.5847/wjem.j.1920-8642.2024.048. World J Emerg Med. 2024. PMID: 38855366 Free PMC article.
-
Cardiac Metabolism, Reprogramming, and Diseases.J Cardiovasc Transl Res. 2024 Feb;17(1):71-84. doi: 10.1007/s12265-023-10432-3. Epub 2023 Sep 5. J Cardiovasc Transl Res. 2024. PMID: 37668897 Review.
-
Myocardial preservation during primary percutaneous intervention: It's time to rethink?Indian Heart J. 2021 Jul-Aug;73(4):395-403. doi: 10.1016/j.ihj.2021.07.008. Epub 2021 Jul 28. Indian Heart J. 2021. PMID: 34474749 Free PMC article. No abstract available.
-
Could Exogenous Insulin Ameliorate the Metabolic Dysfunction Induced by Glucocorticoids and COVID-19?Front Endocrinol (Lausanne). 2021 Jun 18;12:649405. doi: 10.3389/fendo.2021.649405. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34220705 Free PMC article. Review.
-
Stress-Induced Hyperglycaemia in Non-Diabetic Patients with Acute Coronary Syndrome: From Molecular Mechanisms to New Therapeutic Perspectives.Int J Mol Sci. 2021 Jan 14;22(2):775. doi: 10.3390/ijms22020775. Int J Mol Sci. 2021. PMID: 33466656 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous